Suppr超能文献

维生素D在接受人白细胞抗原匹配的异基因干细胞移植治疗急性白血病患者中的相关性。

Relevance of vitamin D in patients undergoing HLA matched allogeneic stem cell transplant for acute leukemia.

作者信息

Jindal Nishant, Saroha Megha, Mirgh Sumeet, Chichra Akanksha, Nayak Lingaraj, Bonda Avinash, Gokarn Anant, Punatar Sachin, Bagal Bhausaheb, Chavan Preeti, Mathew Libin Jacob, Kannan Sadhana, Khattry Navin

机构信息

Department of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India.

Composite Laboratory, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India.

出版信息

Transpl Immunol. 2023 Dec;81:101925. doi: 10.1016/j.trim.2023.101925. Epub 2023 Aug 28.

Abstract

BACKGROUND

In hematopoietic stem cell transplant (HSCT), vitamin D deficiency has been variably associated with increased complications, primarily graft versus host disease (GvHD), with a potential impact on survival. Results from various studies however, have not been consistent. This analysis was conducted to study the impact of peri-transplant vitamin D levels on transplant outcomes in patients with acute leukemia (AL) who underwent HLA matched (related/unrelated) HSCT.

METHODS

This was a single center retrospective study. Patients of AL including Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) or Mixed Phenotypic Acute Leukemia (MPAL) who underwent fully matched or 9/10 transplants (related/unrelated) between 2008 and 2019 were included. Vitamin D deficiency was defined as serum 25-hydroxy vitamin D3 levels ≤20 ng/ml. Those with deficiency received replacement with oral vitamin D at a dose of 60,000 IU weekly for 8 weeks followed by maintenance with daily vitamin D (800 IU/day). Vitamin D levels were repeated at 4 months from start of replacement. For patients who received correction, repeat levels >20 ng/ml were considered replete. Based on vitamin D levels in the peri-transplant period (within 120 days of transplant), patients were categorised as either vitamin D replete (> 20 ng/ml) or deplete (≤ 20 ng/ml). Peri-transplant vitamin D status was correlated with transplant outcomes.

RESULTS

Of the 133 patients included, 31 were deplete (median vitamin D 15.0 ng/ml) and 102 were replete (median vitamin D 34 ng/ml) at time of transplant. Both groups were matched for age, diagnosis, EBMT score and disease risk index (DRI). There were no differences in time to neutrophil or platelet engraftment, CMV reactivation, acute GvHD (aGvHD) or chronic GvHD (cGvHD) between the two groups. Relapse rate, Progression Free Survival (PFS) and Overall Survival (OS) were also comparable between the 2 groups.

CONCLUSION

The incidence of vitamin D deficiency was high in our patient cohort. Patients who were vitamin D deficient at the time of transplant did not have inferior outcomes, suggesting a limited role of vitamin D in influencing transplant outcomes.

摘要

背景

在造血干细胞移植(HSCT)中,维生素D缺乏与并发症增加存在不同程度的关联,主要是移植物抗宿主病(GvHD),这可能对生存率产生影响。然而,各项研究的结果并不一致。本分析旨在研究移植前后维生素D水平对接受HLA匹配(相关/无关)HSCT的急性白血病(AL)患者移植结局的影响。

方法

这是一项单中心回顾性研究。纳入2008年至2019年间接受完全匹配或9/10匹配移植(相关/无关)的AL患者,包括急性淋巴细胞白血病(ALL)、急性髓系白血病(AML)或混合表型急性白血病(MPAL)。维生素D缺乏定义为血清25-羟基维生素D3水平≤20 ng/ml。缺乏者接受口服维生素D替代治疗,剂量为每周60,000 IU,共8周,随后每日维持服用维生素D(800 IU/天)。从开始替代治疗起4个月时复查维生素D水平。对于接受纠正的患者,复查水平>20 ng/ml视为补充充足。根据移植前后时期(移植后120天内)的维生素D水平,将患者分为维生素D充足(>20 ng/ml)或缺乏(≤20 ng/ml)。移植前后维生素D状态与移植结局相关。

结果

纳入的133例患者中,移植时31例缺乏(维生素D中位数为15.0 ng/ml),102例充足(维生素D中位数为34 ng/ml)。两组在年龄、诊断、欧洲血液与骨髓移植协会(EBMT)评分和疾病风险指数(DRI)方面相匹配。两组在中性粒细胞或血小板植入时间、巨细胞病毒(CMV)重新激活、急性移植物抗宿主病(aGvHD)或慢性移植物抗宿主病(cGvHD)方面无差异。两组的复发率、无进展生存期(PFS)和总生存期(OS)也相当。

结论

我们的患者队列中维生素D缺乏的发生率很高。移植时维生素D缺乏的患者结局并不较差,这表明维生素D在影响移植结局方面作用有限。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验